Brief: Silexion Reports Positive Preclinical Data Demonstrating SIL204's Reach
11/09/2025 12:14
Sept 11 (Reuters) - Silexion Therapeutics Corp SLXN.O: SILEXION THERAPEUTICS REPORTS POSITIVE PRECLINICAL DATA DEMONSTRATING SIL204’S REACH AND ACTIVITY IN MAJOR PANCREATIC CANCER METASTATIC SITES FOLLOWING SYSTEMIC ADMINISTRATION SILEXION THERAPEUTICS CORP - ON TRACK FOR PHASE 2/3 TRIAL IN H1 2026 SILEXION THERAPEUTICS CORP - PLANS REGULATORY SUBMISSIONS FOR Q4 2025 AND Q1 2026 SILEXION THERAPEUTICS: NEW DATA DEMONSTRATE SIL204 SUCCESSFULLY REACHES ALL PRIMARY SITES OF PANCREATIC CANCER METASTASIS Source text: ID:nGNX5dVslv Further company coverage: SLXN.O ((Reuters.Briefs@thomsonreuters.com;))